| Autor: |
Gualano, Bruno, Sieczkowska, Sofia M., Lemes, Ítalo Ribeiro, da Silva, Rafael Pires, Pinto, Ana J., Mazzolani, Bruna C., Smaira, Fabiana I., Aikawa, Nadia E., Kupa, Leonard V.K., Pasoto, Sandra G., Medeiros-Ribeiro, Ana C., Saad, Carla G.S., Yuk, Emily F.N., Silva, Clovis A., Swinton, Paul, Hallal, Pedro C., Roschel, Hamilton, Bonfa, Eloisa |
| Předmět: |
|
| Zdroj: |
Journal of Physical Activity & Health; Apr2023, Vol. 20 Issue 4, p311-316, 6p, 1 Chart, 2 Graphs |
| Abstrakt: |
Background: Physical activity associates with improved immunogenicity following a 2-dose schedule of CoronaVac (Sinovac's inactivated SARS-CoV-2 vaccine) in patients with autoimmune rheumatic diseases (ARD). This study evaluates whether physical activity impacts vaccine-induced antibody responses to a booster dose in this population. Methods: This was a phase-4 trial conducted in São Paulo, Brazil. Patients with ARD underwent a 3-dose schedule of CoronaVac. One month after the booster, we assessed seroconversion rates of anti-SARS-CoV-2 S1/S2 IgG, geometric mean titers of anti-S1/S2 IgG, frequency of positive neutralizing antibodies, and neutralizing activity. Physical activity was assessed through questionnaire. Results: Physically active (n = 362) and inactive (n = 278) patients were comparable for most characteristics; however, physically active patients were younger (P <.01) and had a lower frequency of chronic inflammatory arthritis (P <.01). Adjusted models showed that physically active patients had ∼2 times odds of seroconversion rates (OR: 2.09; 95% confidence interval, 1.22 to 3.61), ∼22% greater geometric mean titers of anti-S1/S2 IgG (22.09%; 95% confidence interval, 3.91 to 65.60), and ∼7% greater neutralizing activity (6.76%; 95% confidence interval, 2.80 to 10.72) than inactive patients. Conclusions: Patients with ARD who are physically active have greater odds of experiencing better immunogenicity to a booster dose of CoronaVac. These results support the recommendation of physical activity to improve vaccination responses, particularly for immunocompromised individuals. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
